tiprankstipranks
Trending News
More News >

Solasia Pharma Resumes SP-05 Development with New Fundraising

Story Highlights
Solasia Pharma Resumes SP-05 Development with New Fundraising

Don’t Miss TipRanks’ Half-Year Sale

Solasia Pharma KK ( (JP:4597) ) has provided an announcement.

Solasia Pharma K.K. announced a fundraising initiative through the issuance of warrants to Macquarie Bank Limited, aiming to raise JPY 2,049 million. The funds will be used to resume the development of SP-05, a colorectal cancer treatment, after previous clinical trials did not meet primary endpoints. The decision to continue development follows a reanalysis by Isofol Medical AB, the licensor of SP-05, which led to the resumption of clinical trials. This move is expected to enhance Solasia’s position in the oncology market and potentially bring a new treatment option for colorectal cancer.

More about Solasia Pharma KK

Solasia Pharma K.K. is a specialty pharmaceutical company based in Asia, primarily focused on developing treatments for cancer. The company is headquartered in Tokyo, Japan, and is involved in the development of pharmaceuticals and medical devices, with a market focus on oncology.

YTD Price Performance: 18.13%

Average Trading Volume: 271

Technical Sentiment Signal: Hold

Current Market Cap: €55.1M

Learn more about 4597 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1